Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

Abstract Bevacizumab (BEV) combined with standard chemotherapy with carboplatin and paclitaxel (CP) as the front-line treatment for newly diagnosed advanced-stage epithelial ovarian cancer (EOC) is a promising treatment option. In Thailand, combined BEV and CP for patients with high-risk EOC is not...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kanyarat Katanyoo, Usa Chaikledkaew, Nutthaporn Chandeying
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2025-03-01
coleção:	Scientific Reports
Assuntos:	Ovarian cancer Bevacizumab Cost-effectiveness Quality adjusted life year Thailand
Acesso em linha:	https://doi.org/10.1038/s41598-025-94455-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!